And for Investors – PPM

bioZhena venture – synopsis of financial projections, big picture: https://biozhena.wordpress.com/2015/07/09/biozhena-venture-on-equitynet/

Quick overview of PPM: https://biozhena.wordpress.com/we-pitch-the-biozhena-investment-opportunity/

Transforming Female Reproductive Health Management prt scr New mostly narrated slides 2017 – 03e2

Sample PPM document for preview before it gets assigned to an individual investor is no longer provided. Serious investor, please request your copy by email from Vaclav at vaclav@biozhena.com

Citing from Introduction:

The Company, a Colorado C-Corporation (“the Company”), is offering 1,000,000 shares of its common stock, at the price of $ 3.00 per share (shares of the Offering) to finance the manufacturing of medical consumer products previously demonstrated in proof-of-concept studies with pre-production prototypes, in studies that were used to obtain FDA 510k clearance.  The shares sold in the Offering, if fully subscribed, will constitute 10% of the Company’s shares as of the date of issuance, and/or 20% with the associated warrants. The preferred minimum investment is $ 250,000.  However, the Company may permit purchases of a lesser amount for fewer shares, at its discretion.  (See Subscription Agreement in Exhibit 1.)  Each purchased share will be accompanied by a Warrant exercisable within 1 year of the date of the Subscription Agreement, at the same $3.00 price (see Exhibit 2). A different deal could be signed with a large investor.

The Offering will remain open until fully subscribed, or until closed by the Company, at its sole discretion. This Offering may be a bridge to a strategic partnership such as an Investment Banker has in fact proposed (investment of up to $25 million).

The offered Warrants mean that the start-up investors are in effect offered 20% of the equity, which the investors can purchase in a staged manner at the same price of $3.00 per share.

Furthermore, as an alternative to receiving shares of stock for the invested dollars, the Company is prepared to negotiate with investors in case they may be interested in royalty-based investment, aiming at regular income from gross revenues after breakeven.

Yet another option the Company is open to is a pre-agreed buyback of shares at an agreed time after breakeven.

Advertisements

%d bloggers like this: